Glenmark Pharmaceuticals launches Type 2 diabetes drug Zita D in India

Glenmark Pharmaceuticals has launched Zita D the brand name for Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination in India for the treatment of Type 2 diabetes in adult patients, especially those with comorbidities.

According to Glenmark Pharmaceuticals, Zita D has to be taken daily once by Type 2 diabetic patients under prescription for enhancing glycemic control and the prevention of complications.

Alok Malik — Glenmark Pharmaceuticals EVP & Business Head of India Formulations said: “Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities.

“Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities.”

Teneligliptin is a broadly used inhibitor of dipeptidyl peptidase 4 (DPP4), while Dapagliflozin is a commonly prescribed Sodium glucose co‐transporter 2 (SGLT‐2i) inhibitor for patients with diabetes in India.

Glenmark Pharmaceuticals said that Zita D costs around INR 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for the fixed dose combination of Teneligliptin 20 mg + Dapagliflozin 10 mg, per day.